Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights from FOURIER
Michelle L. O'Donoghue, Sergio Fazio, Robert P. Giugliano · Post-hoc analysis of RCT
BlueRipple Assessment
Note: This source file (o’kelly-et-al-2022.md) is a duplicate of odonoghue-et-al-2019.md. Both files share the same shortCitation (“O’Donoghue et al., 2019”), the same PubMed URL (https://pubmed.ncbi.nlm.nih.gov/30586765/), and the same underlying article — the FOURIER Lp(a) sub-analysis. The source file appears to have been misfiled under a variant author name.
See the canonical review at odonoghue-et-al-2019 for the full analysis.
The original source
O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial. Circulation. 2019;139(12):1483-1492.
BlueRipple Health provides consumer education and research synthesis for informed health advocacy. This is not medical advice. Discuss all health decisions with a qualified clinician.